Analyst Activity – Wedbush Reiterates Outperform on NASDAQ:UMRX – Unum Therapeutics (NASDAQ:UMRX)

Analyst Ratings For NASDAQ:UMRX – Unum Therapeutics (NASDAQ:UMRX)

Story continues below

Today, Wedbush reiterated its Outperform rating on NASDAQ:UMRX – Unum Therapeutics (NASDAQ:UMRX) with a price target of $18.00.

Some recent analyst ratings include

  • 5/15/2018-Wedbush Reiterated Rating of Outperform.
  • 4/23/2018-Cowen initiated coverage with a Market Perform rating.
  • 4/23/2018-Morgan Stanley initiated coverage with a Overweight rating.
  • 4/23/2018-SunTrust Banks initiated coverage with a Buy rating.


  • On 4/3/2018 Liam Ratcliffe, Director, bought 550,000 with an average share price of $12.00 per share and the total transaction amounting to $6,600,000.00.
  • On 4/3/2018 Venture Fund Ix L.P. Atlas, Major Shareholder, bought 94,052 with an average share price of $12.00 per share and the total transaction amounting to $1,128,624.00.

Recent Trading Activity for NASDAQ:UMRX – Unum Therapeutics (NASDAQ:UMRX)
Shares of NASDAQ:UMRX – Unum Therapeutics closed the previous trading session at 10.57 up +0.01 0.09% with 10.40999984741211 shares trading hands.

An ad to help with our costs